Skip to content

house · Committee report

H. Rept. 119-352

GIVE KIDS A CHANCE ACT OF 2025

2025-10-31

Committees

Associated legislation

Text

Purpose and Summary

H.R. 1262 provides the Food and Drug Administration (FDA) with additional authority to require pediatric cancer trials for new combinations of drug therapies. The legislation also authorizes the FDA to take enforcement action against companies that fail to meet pediatric study requirements under the Pediatric Research Equity Act (PREA) and requires the FDA to report on enforcement of PREA. Additionally, the legislation reauthorizes the FDA rare pediatric disease priority review voucher (PRV) program through Fiscal Year 2029 and clarifies that orphan drug exclusivity applies to the approved indication, rather than the potentially broader designation. This legislation also makes a technical correction to the existing authorization of appropriations for the National Institutes of Health (NIH) to fund studies of drugs in children. In addition, this legislation allows the Secretary of Health and Human Services (HHS) to collect registration fees from members of the Organ Procurement and Transplantation Network (OPTN) and distribute these fees to support the operation of the OPTN for a period of 3 years. This legislation also directs the FDA to establish an office in an Abraham Accord country to enhance facilitation with the agency. Lastly, this legislation requires FDA to disclose to certain generic drug applicants what ingredients, if any, cause a drug to be quantitatively or qualitatively different from the listed drug for purposes of establishing sameness in formulation, and the specific amount of the difference.

Background and Need for Legislation

Approximately 1,600 American children and adolescents die each year from cancer and, in 2024, roughly 14,910 children and adolescents were diagnosed with cancer.\1\ In recent years, the 5-year survival rates for most childhood cancers have improved--between 1975 and 2022, the cancer mortality rate among children and adolescents decreased from 5.1 per 100,000 children and adolescents to 2.2 per 100,000 children and adolescents.\2\ Though cancer outcomes have generally improved, the rate of improvement in survival has more recently slowed and more than one-half of pediatric cancer survivors experience serious long-term effects of their cancer and its therapy.\3\ In addition, there remain disparities between the outcomes and cancer-related mortality across cancer types, ultimately requiring more research and treatment development. Combination therapy, a treatment method that utilizes two or more therapeutic agents, is considered a cornerstone of cancer therapy.\4\ Combination therapies are often more effective than single agent therapy and demonstrate lower levels of toxicity during long-term treatment.\5\ Currently, the FDA is only authorized to require pediatric trials of single drug cancer treatments. --------------------------------------------------------------------------- \1\American Cancer Society, Cancer Facts & Figures 2024 (2024), https://www.cancer.org/ content/dam/cancer-org/research/cancer-facts-and-statistics/annual- cancer-facts-and-figures/2024/2024-cancer-facts-and-figures-acs.pdf; see also NATIONAL INSTITUTE OF HEALTH (NIH), National Cancer Institute, Cancer in Children and Adolescents (Aug. 27, 2024), https:// www.cancer.gov/types/childhood-cancers/child-adolescent-cancers-fact- sheet. \2\NIH, National Cancer Institute, Cancer in Children and Adolescents (Aug. 27, 2024), https://www.cancer.gov/types/childhood- cancers/child-adolescent-cancers-fact-sheet. \3\Erin Butler et al., ``Recent progress in the treatment of cancer in children,'' American Cancer Society Journals, 2021, https:// acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21665. \4\Rexa Bayat Mokhtari et al., Combination therapy in combating cancer, Oncotarget (Mar. 30, 2017), https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC5514969/. \5\Yiling Wang & Audrey Minden, Current Molecular Combination Therapies Used for the Treatment of Breast Cancer, International Journal of Molecular Sciences (Sept. 20, 2022), https:// www.ncbi.nlm.nih.gov/pmc/articles/PMC9569555/ #::text=Recently%2C%20combination%20 therapies%20%28in%20which%20two%20or%20more,demonstrate%20lower%20levels %20of%20 toxicity%20during%20long-term%20treatment. --------------------------------------------------------------------------- In addition, roughly 15 million American children are living with a rare disease, yet 95 percent of rare diseases do not have an FDA-approved treatment.\6\ The FDA rare pediatric disease priority review voucher (PRV) program, which sunset after December 20, 2024, aims to incentivize drug development of treatments and cures for rare pediatric diseases by awarding a priority review voucher for a qualifying drug or biological product that targets a rare pediatric disease.\7\ Since the program was first authorized in 2012, there have been over 60 PRVs awarded to sponsors that developed treatments for pediatric rare diseases.\8\ --------------------------------------------------------------------------- \6\National Organization for Rare Disorders (NORD), Congress: Reauthorize the Rare Pediatric Disease Priority Review Voucher Program (Jul. 23, 2024), https://rarediseases.org/rare-pediatric-disease-prv- program/. \7\U.S. FOOD AND DRUG ADMINISTRATION, Rare Pediatric Disease Designation and Priority Review Voucher Programs (Sept. 27, 2024), https://www.fda.gov/industry/medical-products-rare-diseases-and- conditions/rare-pediatric-disease-designation-and-priority-review- voucher- programs. \8\Between 2012 and August 28, 2025, there have been a total of 48 Rare Pediatric Disease (RPD) PRVs issued through FDA's Center for Drug Evaluation and Research and a total of 13 RPD PRVs issued through FDA's Center for Biologics Evaluation and Research and published on the Federal Register. See Notice, 79 Fed. Reg. 14055 (Mar. 12, 2014); see also 80 Fed. Reg. 18628 (Apr. 7, 2015); 80 Fed. Reg. 18628 (Apr. 7, 2015); 80 Fed. Reg. 58489 (Sept. 29, 2015); 80 Fed. Reg. 71811 (Nov. 17, 2015); 81 Fed. Reg. 71511 (Oct. 17, 2016); 82 Fed. Reg. 12614 (Mar. 6, 2017); 82 Fed. Reg. 19052 (Apr. 25, 2017); 82 Fed. Reg. 28860 (Jun. 26, 2017); 82 Fed. Reg. 42686 (Sept. 11, 2017); 82 Fed. Reg. 59622 (Dec. 15, 2017); 83 Fed. Reg. 125 (Jan. 2, 2018); 83 Fed. Reg. 34139 (Jul. 19, 2018); 83 FR 40524 (Aug. 15, 2018); 83 Fed. Reg. 53880 (Oct. 25, 2018); 83 Fed. Reg. 64133 (Dec. 13, 2018); 84 Fed. Reg. 11985 (Mar. 29, 2019); 84 Fed. Reg. 29520 (Jun. 24, 2019); 84 Fed. Reg. 31324 (Jul. 1, 2019); 85 Fed. Reg. 3935 (Jan. 23, 2020); 85 Fed. Reg. 52354 (Aug. 25, 2020); 85 Fed. Reg. 55304 (Sept. 4, 2020); 85 Fed. Reg. 57217 (Sept. 15, 2020); 85 Fed. Reg. 57864 (Sept. 16, 2020); 85 Fed. Reg. 78859 (Dec. 7, 2020); 85 Fed. Reg. 81929 (Dec. 17, 2020); 85 Fed. Reg. 81933 (Dec. 17, 2020); 86 Fed. Reg. 9514 (Feb. 16, 2021); 86 Fed. Reg. 14125 (Mar. 12, 2021); 86 Fed. Reg. 14130 (Mar. 12, 2021); 86 Fed. Reg. 35307 (Jul. 2, 2021); 86 Fed. Reg. 59405 (Oct. 27, 2021); 87 Fed. Reg. 52782 (Aug. 29, 2022); 87 Fed. Reg. 54515 (Sept. 6, 2022); 87 Fed. Reg. 54700 (Sept. 7, 2022); 87 Fed. Reg. 61090 (Oct. 7, 2022); 87 Fed. Reg. 61090 (Oct. 7, 2022); 88 Fed. Reg. 16266 (Mar. 16, 2023); 88 Fed. Reg. 16274 (Mar. 16, 2023); 88 Fed. Reg. 19150 (Mar. 30, 2023); 88 Fed. Reg. 24806 (Apr. 24, 2023); 88 Fed. Reg. 37068 (Jun. 6, 2023); 88 Fed. Reg. 45430 (Jul. 17, 2023); 88 Fed. Reg. 61598 (Sept. 7, 2023); 88 Fed. Reg. 61600 (Sept. 7, 2023); 88 Fed. Reg. 84337 (Dec. 5, 2023); 89 Fed. Reg. 1097 (Jan. 9, 2024); 89 Fed. Reg. 1924 (Jan. 11, 2024); 89 Fed. Reg. 1925 (Jan. 11, 2024); 89 Fed. Reg. 25634 (Apr. 11, 2024); 89 Fed. Reg. 27767 (Apr. 18, 2024); 89 Fed. Reg. 42472 (May 15, 2024); 89 Fed. Reg. 42888 (May 16, 2024); 89 Fed. Reg. 68909 (Aug. 28, 2024); 89 Fed. Reg. 83023 (Oct. 15, 2024); 89 Fed. Reg. 83020 (Oct. 15, 2024); 89 Fed. Reg. 95219 (Dec. 2, 2024); 90 Fed. Reg. 2008 (Jan. 10, 2025); 90 Fed. Reg. 3880 (Jan. 15, 2025); 90 Fed. Reg. 11992 (Mar. 13, 2025); and 90 Fed. Reg. 42018 (Aug. 28, 2025). --------------------------------------------------------------------------- In addition, FDA currently requires certain formulations of generic medicines to demonstrate qualitative and quantitative sameness of inactive ingredients with their brand-name reference product. Generic drug developers often lack information about these inactive ingredients, which can result in inefficiencies in agency review, slower approvals, and delayed access of generic drugs for patients. By extending FDA's authority to require completion of pediatric studies of combination therapies, as well as clarifying that Orphan Drug Exclusivity only applies to the same approved use or indication within such rare disease or condition, as opposed to the entire disease or condition, reauthorizing the rare pediatric disease priority review voucher (PRV) program, providing a technical correction to the authorization of appropriations to support efforts at the NIH to research and improve the safety and efficacy of medication use for children, and establishing an FDA office in an Abraham Accords country to facilitate innovation, the Give Kids a Chance Act of 2025 seeks to accelerate the development of novel, safe, and effective treatments and improve outcomes for pediatric cancer and rare pediatric diseases. Further, allowing the Department of Health and Human Services (HHS) to collect and distribute registration fees itself to support the OPTN operations, as well as increasing transparency and reducing burdens related to generic drug approvals, will continue our shared missions to increase organ transplant rates and improve access to timely, cost-efficient treatments, respectively-- ultimately leading to improved health outcomes.

Committee Action

On June 24, 2025, the Subcommittee on Health held a hearing related to H.R. 1262. The title of the hearing was ``The Fiscal Year 2026 Department of Health and Human Services Budget.'' The Subcommittee received testimony from: The Honorable Robert F. Kennedy, Jr., Secretary, U.S. Department of Health and Human Services. On September 17, 2025, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 1262, as amended, favorably reported to the House by a record vote of 47 yeas and 0 nays.

Committee Votes

Clause 3(b) of rule XIII requires the Committee to list the record votes on the motion to report legislation and amendments thereto. The following reflects the record votes taken during the Committee consideration: Oversight Findings and Recommendations Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of rule XIII, the Committee held a hearing and made findings that are reflected in this report. New Budget Authority, Entitlement Authority, and Tax Expenditures Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R. 1262 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues.

Congressional Budget Office Estimate

Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available. Federal Mandates Statement The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office pursuant to section 423 of the Unfunded Mandates Reform Act. Statement of General Performance Goals and Objectives Pursuant to clause 3(c)(4) of rule XIII, the general performance goal or objective of this legislation is to expand FDA authority related to pediatric cancer and rare disease research and development, allow the Secretary of Health and Human Services (HHS) to collect registration fees from OPTN members to support the operation of the OPTN, and increase access to generic drugs. Duplication of Federal Programs Pursuant to clause 3(c)(5) of rule XIII, no provision of H.R. 1262 is known to be duplicative of another Federal program, including any program that was included in a report to Congress pursuant to section 21 of Public Law 111-139 or the most recent Catalog of Federal Domestic Assistance. Related Committee and Subcommittee Hearings Pursuant to clause 3(c)(6) of rule XIII, the following related hearing was used to develop or consider H.R. 1262: On June 24, 2025, the Subcommittee on Health held a hearing related to H.R. 1262. The title of the hearing was ``The Fiscal Year 2026 Department of Health and Human Services Budget.'' The Subcommittee received testimony from: The Honorable Robert F. Kennedy, Jr., Secretary, U.S. Department of Health and Human Services. Committee Cost Estimate Pursuant to clause 3(d)(1) of rule XIII, the Committee adopts as its own the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974. At the time this report was filed, the estimate was not available. Earmark, Limited Tax Benefits, and Limited Tariff Benefits Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the Committee finds that H.R. 1262 contains no earmarks, limited tax benefits, or limited tariff benefits. Advisory Committee Statement No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act were created by this legislation. Applicability to Legislative Branch The Committee finds that the legislation does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act. Section-by-Section Analysis of the Legislation Section 1. Short title; table of contents Section 1 provides a short title of ``Give Kids a Chance Act of 2025'' and the table of contents for this Act. Section 2. Research into pediatric uses of drugs; additional authorities of Food and Drug Administration regarding molecularly targeted cancer drugs Section 2 provides the Food and Drug Administration (FDA) the authority to require pediatric cancer trials for new drugs that are used in combination with active ingredients that meet the standard of care for targeting pediatric cancer or have been approved to treat adult cancer and are directed at molecular targets for pediatric cancer. It would also require the Government Accountability Office (GAO) to conduct a study and report to Congress on the effectiveness of the requirements outlined in this section in the development of drugs and biological products for pediatric cancer indications. Section 3. Ensuring completion of pediatric study requirements Section 3 provides the FDA the authority to enforce against companies that fail to meet pediatric study requirements. The Secretary of the Department of Health and Human Services shall perform due diligence before concluding failure to meet requirements. Section 4. FDA report on PREA enforcement Section 4 requires the FDA to report on enforcement of the Pediatric Research Equity Act (PREA). Section 5. Extension of authority to issue priority review vouchers to encourage treatments for rare pediatric diseases Section 5 extends the FDA priority review voucher program through September 30, 2029, to incentivize the development of drugs for rare pediatric diseases. It also requires a study from the GAO on the effectiveness of the pediatric PRV program. Section 6. Limitations on exclusive approval of licensure of orphan drugs Section 6 clarifies that orphan drug exclusivity applies to the approved indication, rather than the potentially broader designation, in alignment with the FDA's interpretation. Section 7. Program for pediatric studies of drugs Section 7 makes a technical correction to the existing authorization of appropriations for the National Institutes of Health (NIH) to research studies of drugs in children. Section 8. Organ Procurement and Transplantation Network Section 8 allows the Secretary of Health and Human Services to collect registration fees from any member of the Organ Procurement Transplantation Network (OPTN) for each transplant candidate such member places on the list and distribute these fees to support the operation of OPTN, for a period of 3 years. Section 9. Establishment of Abraham Accords Office within Food and Drug Administration Section 9 would require the Food and Drug Administration to establish an office in an Abraham Accords country to enhance facilitation with the agency and require the Secretary of Health and Human Services to submit a report to Congress to evaluate the office's progress. Section 10. Increasing transparency in generic drug applications Section 10 requires FDA to disclose to certain formulations of generic drug applicants what ingredients, if any, cause a drug to be quantitatively or qualitatively different from the listed drug for purposes of establishing sameness in formulation, and the specific amount of the difference. Section 11. Medicare Improvement Fund Section 11 adjusts the amount of funding in the Medicare Improvement Fund from $1.804 billion to $3.047 billion. Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (existing law proposed to be omitted is enclosed in black brackets, new matter is printed in italics, and existing law in which no change is proposed is shown in roman): FEDERAL FOOD, DRUG, AND COSMETIC ACT * * * * * * * CHAPTER III--PROHIBITED ACTS AND PENALTIES * * * * * * * penalties Sec. 303. (a)(1) Any person who violates a provision of section 301 shall be imprisoned for not more than one year or fined not more than $1,000, or both. (2) Notwithstanding the provisions of paragraph (1) of this section, if any person commits such a violation after a conviction of him under this section has become final, or commits such a violation with the intent to defraud or mislead, such person shall be imprisoned for not more than three years or fined not more than $10,000 or both. (b)(1) Notwithstanding subsection (a), any person who violates section 301(t) by-- (A) knowingly importing a drug in violation of section 801(d)(1), (B) knowingly selling, purchasing, or trading a drug or drug sample or knowingly offering to sell, purchase, or trade a drug or drug sample, in violation of section 503(c)(1), (C) knowingly selling, purchasing, or trading a coupon, knowingly offering to sell, purchase, or trade such a coupon, or knowingly counterfeiting such a coupon, in violation of section 503(c)(2), or (D) knowingly distributing drugs in violation of section 503(e)(1), shall be imprisoned for not more than 10 years or fined not more than $250,000, or both. (2) Any manufacturer or distributor who distributes drug samples by means other than the mail or common carrier whose representative, during the course of the representative's employment or association with that manufacturer or distributor, violated section 301(t) because of a violation of section 503(c)(1) or violated any State law prohibiting the sale, purchase, or trade of a drug sample subject to section 503(b) or the offer to sell, purchase, or trade such a drug sample shall, upon conviction of the representative for such violation, be subject to the following civil penalties: (A) A civil penalty of not more than $50,000 for each of the first two such violations resulting in a conviction of any representative of the manufacturer or distributor in any 10-year period. (B) A civil penalty of not more than $1,000,000 for each violation resulting in a conviction of any representative after the second conviction in any 10- year period. For the purposes of this paragraph, multiple convictions of one or more persons arising out of the same event or transaction, or a related series of events or transactions, shall be considered as one violation. (3) Any manufacturer or distributor who violates section 301(t) because of a failure to make a report required by section 503(d)(3)(E) shall be subject to a civil penalty of not more than $100,000. (4)(A) If a manufacturer or distributor or any representative of such manufacturer or distributor provides information leading to the institution of a criminal proceeding against, and conviction of, any representative of that manufacturer or distributor for a violation of section 301(t) because of a sale, purchase, or trade or offer to purchase, sell, or trade a drug sample in violation of section 503(c)(1) or for a violation of State law prohibiting the sale, purchase, or trade or offer to sell, purchase, or trade a drug sample, the conviction of such representative shall not be considered as a violation for purposes of paragraph (2). (B) If, in an action brought under paragraph (2) against a manufacturer or distributor relating to the conviction of a representative of such manufacturer or distributor for the sale, purchase, or trade of a drug or the offer to sell, purchase, or trade a drug, it is shown, by clear and convincing evidence-- (i) that the manufacturer or distributor conducted, before the institution of a criminal proceeding against such representative for the violation which resulted in such conviction, an investigation of events or transactions which would have led to the reporting of information leading to the institution of a criminal proceeding against, and conviction of, such representative for such purchase, sale, or trade or offer to purchase, sell, or trade, or (ii) that, except in the case of the conviction of a representative employed in a supervisory function, despite diligent implementation by the manufacturer or distributor of an independent audit and security system designed to detect such a violation, the manufacturer or distributor could not reasonably have been expected to have detected such violation, the conviction of such representative shall not be considered as a conviction for purposes of paragraph (2). (5) If a person provides information leading to the institution of a criminal proceeding against, and conviction of, a person for a violation of section 301(t) because of the sale, purchase, or trade of a drug sample or the offer to sell, purchase, or trade a drug sample in violation of section 503(c)(1), such person shall be entitled to one-half of the criminal fine imposed and collected for such violation but not more than $125,000. (6) Notwithstanding subsection (a), any person who is a manufacturer or importer of a prescription drug under section 804(b) and knowingly fails to comply with a requirement of section 804(e) that is applicable to such manufacturer or importer, respectively, shall be imprisoned for not more than 10 years or fined not more than $250,000, or both. (7) Notwithstanding subsection (a)(2), any person that knowingly and intentionally adulterates a drug such that the drug is adulterated under subsection (a)(1), (b), (c), or (d) of section 501 and has a reasonable probability of causing serious adverse health consequences or death to humans or animals shall be imprisoned for not more than 20 years or fined not more than $1,000,000, or both. (8) Notwithstanding subsection (a), any person who violates section 301(i)(3) by knowingly making, selling or dispensing, or holding for sale or dispensing, a counterfeit drug, or who violates section 301(fff)(3) by knowingly making, selling or dispensing, or holding for sale or dispensing, a counterfeit device, shall be imprisoned for not more than 10 years or fined in accordance with title 18, United States Code, or both. (c) No person shall be subject to the penalties of subsection (a)(1) of this section, (1) for having received in interstate commerce any article and delivered it or proffered delivery of it, if such delivery or proffer was made in good faith, unless he refuses to furnish on request of an officer or employee duly designated by the Secretary the name and address of the person from whom he purchased or received such article and copies of all documents, if any there be, pertaining to the delivery of the article to him; or (2) for having violated section 301(a) or (d), if he establishes a guaranty or undertaking signed by, and containing the name and address of, the person residing in the United States from whom he received in good faith the article, to the effect, in case of an alleged violation of section 301(a), that such article is not adulterated or misbranded, within the meaning of this Act, designating this Act, or to the effect, in case of an alleged violation of section 301(d), that such article is not an article which may not, under the provisions of section 404 or 505, be introduced into interstate commerce; or (3) for having violated section 301(a), where the violation exists because the article is adulterated by reason of containing a color additive not from a batch certified in accordance with regulations promulgated by the Secretary under this Act, if such person establishes a guaranty or undertaking signed by, and containing the name and address of, the manufacturer of the color additive, to the effect that such color additive was from a batch certified in accordance with the applicable regulations promulgated by the Secretary under this Act; or (4) for having violated section 301 (b), (c), or (k) by failure to comply with section 502(f) in respect to an article received in interstate commerce to which neither section 503(a) nor section 503(b)(1) is applicable, if the delivery or proffered delivery was made in good faith and the labeling at the time thereof contained the same directions for use and warning statements as were contained in the labeling at the time of such receipt of such article; or (5) for having violated section 301(i)(2) if such person acted in good faith and had no reason to believe that use of the punch, die, plate, stone, or other thing involved would result in a drug being a counterfeit drug, or for having violated section 301(i)(3) if the person doing the act or causing it to be done acted in good faith and had no reason to believe that the drug was a counterfeit drug; or (6) for having violated section 301(fff)(2) if such person acted in good faith and had no reason to believe that use of the punch, die, plate, stone, or other thing involved would result in a device being a counterfeit device, or for having violated section 301(fff)(3) if the person doing the act or causing it to be done acted in good faith and had no reason to believe that the device was a counterfeit device. (d) No person shall be subject to the penalties of subsection (a)(1) of this section for a violation of section 301 involving misbranded food if the violation exists solely because the food is misbranded under section 403(a)(2) because of its advertising. (e)(1) Except as provided in paragraph (2), whoever knowingly distributes, or possesses with intent to distribute, human growth hormone for any use in humans other than the treatment of a disease or other recognized medical condition, where such use has been authorized by the Secretary of Health and Human Services under section 505 and pursuant to the order of a physician, is guilty of an offense punishable by not more than 5 years in prison, such fines as are authorized by title 18, United States Code, or both. (2) Whoever commits any offense set forth in paragraph (1) and such offense involves an individual under 18 years of age is punishable by not more than 10 years imprisonment, such fines as are authorized by title 18, United States Code, or both. (3) Any conviction for a violation of paragraphs (1) and (2) of this subsection shall be considered a felony violation of the Controlled Substances Act for the purposes of forfeiture under section 413 of such Act. (4) As used in this subsection the term ``human growth hormone'' means somatrem, somatropin, or an analogue of either of them. (5) The Drug Enforcement Administration is authorized to investigate offenses punishable by this subsection. (f)(1)(A) Except as provided in subparagraph (B), any person who violates a requirement of this Act which relates to devices shall be liable to the United States for a civil penalty in an amount not to exceed $15,000 for each such violation, and not to exceed $1,000,000 for all such violations adjudicated in a single proceeding. For purposes of the preceding sentence, a person accredited under paragraph (2) of section 704(g) who is substantially not in compliance with the standards of accreditation under such section, or who poses a threat to public health or fails to act in a manner that is consistent with the purposes of such section, shall be considered to have violated a requirement of this Act that relates to devices. (B) Subparagraph (A) shall not apply-- (i) to any person who violates the requirements of section 519(a) or 520(f) unless such violation constitutes (I) a significant or knowing departure from such requirements, or (II) a risk to public health, (ii) to any person who commits minor violations of section 519(e) or 519(g) (only with respect to correction reports) if such person demonstrates substantial compliance with such section, or (iii) to violations of section 501(a)(2)(A) which involve one or more devices which are not defective. (2)(A) Any person who introduces into interstate commerce or delivers for introduction into interstate commerce an article of food that is adulterated within the meaning of section 402(a)(2)(B) or any person who does not comply with a recall order under section 423 shall be subject to a civil money penalty of not more than $50,000 in the case of an individual a

Source: https://api.congress.gov/v3/committee-report/119/hrpt/352